Zepbound 5 MG/0.5 ML pen 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FM9E8
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $123,775
Award facts
- Contract value 100% obligated
- $123,774.53 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 8, 2026, the Defense Logistics Agency awarded a delivery order valued at $123,774.53 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injections. The contract employs firm fixed-price pricing and is not set aside for any specific business category, indicating full and open competition. Performance will be completed at AmerisourceBergen Drug Corp's facility in Conshohocken, Pennsylvania, with an ultimate completion date of January 9, 2026. This delivery order is issued under the company's parent organization, Cencora, Inc. (doing business as AmerisourceBergen), which holds a substantial Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2031, serving as the overarching vehicle for pharmaceutical and medical supply procurement.
AmerisourceBergen serves as a critical pharmaceutical distributor for federal military healthcare systems through its comprehensive IDC, which enables the company to supply an extensive range of medications, vaccines, syringes, and medical devices across multiple therapeutic domains to support Defense Health Agency operations, U.S. Coast Guard, and other government healthcare institutions globally. This specific delivery order for Zepbound, a GLP-1 receptor agonist medication used in diabetes and weight management treatment, exemplifies the company's role in providing specialty pharmaceutical products to support military personnel and veteran healthcare needs.
Quick answers
Who was awarded contract SPE2DR26FM9E8?
SPE2DR26FM9E8 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26FM9E8 worth?
The government has obligated $123,775 on SPE2DR26FM9E8.
Is contract SPE2DR26FM9E8 an order under another contract?
Yes. SPE2DR26FM9E8 is a delivery order under SPE2DR25D2211, an indefinite delivery contract.
Was contract SPE2DR26FM9E8 competed?
The extent of competition for SPE2DR26FM9E8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award